(C) SGS 2017 influenza virus testing facilitySGS Clinical: New H3N2-type virus as biomarker
for influenza testing

January 2017. SGS announced the forthcoming availability of a new strain of influenza virus. The synthetic virus may be used to test the efficacy of both novel influenza drugs and vaccines in healthy volunteers. The new agent is a H3N2 type virus, which represents one of the common current circulating strains of influenza of a pandemic origin. Its manufacture has been undertaken by SGS in accordance with Good Manufacturing Practice to ensure that strict regulatory guidelines in both the US and EU (FDA and EMA) are met, and the virus is currently undergoing an array of both adventitious and purity tests. It is anticipated that final safety and activity data from the first-in-human studies using the virus will be announced in a presentation at the World Vaccine Congress, to be held in Washington DC, in April 2017.

Located in Antwerp’s Stuivenberg Hospital, Belgium, SGS has a fully accredited, containment-Level 2, 20-bed human challenge unit, providing full isolation capabilities and offers an entire range of services for any challenge trial performed with the new influenza agent.

Source: SGS 

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Eurofins: Sustainable profitability – albeit not for investors in a hurry

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

System Biology In Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Thermo Fisher’s BRIMS-Strategy Under Testing

Stem Cells and Vaccines in Biomanufacturing

The Laboratory Furniture Market -Assessment and Outlook

Instrument Standards: We need the users, and users have to adopt it

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts

Eurofins expands with diagnostics for rare diseases in the U.S.

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.